Evidence map›Paper›PMID 26899863›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2016

Transportan 10 improves the anticancer activity of cisplatin.

Rusiecka Izabela, Ruczyński Jarosław, Alenowicz Magdalena, Rekowski Piotr, Kocić Ivan

Erratum issuedAbstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Peptide cargo administration: current state and applications.Applied microbiology and biotechnology · 2023
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Rusiecka IzabelaDepartment of Pharmacology, Medical University of Gdańsk, Gdańsk, Poland.
Ruczyński JarosławDepartment of Chemistry, University of Gdańsk, Gdańsk, Poland.
Alenowicz MagdalenaDepartment of Chemistry, University of Gdańsk, Gdańsk, Poland.
Rekowski PiotrDepartment of Chemistry, University of Gdańsk, Gdańsk, Poland.
Kocić IvanDepartment of Pharmacology, Medical University of Gdańsk, Gdańsk, Poland. ikocic@gumed.edu.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this paper was to examine whether cell-penetrating peptides (CPPs) such as transportan 10 (TP10) or protein transduction domain (PTD4) may improve the anticancer activity of cisplatin (cPt). The complexes of TP10 or PTD4 with cPt were used in the experiments. They were carried out on two non-cancer (HEK293 (human embryonic kidney) and HEL299 (human embryo lung)) and two cancer (HeLa (human cervical cancer) and OS143B (human osteosarcoma 143B)) cell lines. Both complexes were tested (MTT assay) with respect to their anticancer or cytotoxic actions. TAMRA (fluorescent dye)-stained preparations were visualized in a fluorescence microscope. The long-term effect of TP10 + cPt and its components on non-cancer and cancer cell lines was observed in inverted phase contrast microscopy. In the MTT test (cell viability assay), the complex of TP10 + cPt produced a more potent effect on the cancer cell lines (HeLa, OS143B) in comparison to that observed after separate treatment with TP10 or cPt. At the same time, the action of the complex and its components was rather small on non-cancer cell lines. On the other hand, a complex of another CPP with cPt, i.e., PTD4 + cPt, was without a significant effect on the cancer cell line (OS143B). The images of the fluorescent microscopy showed TAMRA-TP10 or TAMRA-TP10 + cPt in the interior of the HeLa cells. In the case of TAMRA-PTD4 or TAMRA-PTD4 + cPt, only the first compound was found inside the cancer cell line. In contrast, none of the tested compounds gained access to the interior of the non-cancer cells (HEK293, HEL299). Long-term incubation with the TP10 + cPt (estimated by inverted phase contrast microscopy) lead to an enhanced action of the complex on cell viability (decrease in the number of cells and change in their morphology) as compared with that produced by each single agent. With regard to the tested CPPs, only TP10 improved the anticancer activity of cisplatin if both compounds were used in the form of a complex. Additionally, the complex was relatively safe for non-cancer cells. What is more, TP10 also produced an anticancer effect on HeLa and OS143B cell lines.

Indexed as

Antineoplastic AgentsCell LineCell Line, TumorCell-Penetrating PeptidesCell SurvivalCisplatinDrug SynergismHumansRecombinant Fusion ProteinsRhodamines5-carboxytetramethylrhodamine succinimidyl esterAntineoplastic AgentsCell-Penetrating PeptidesCisplatinRecombinant Fusion ProteinsRhodaminestransportan-10Cell-penetrating peptides (CPPs)Click chemistryHEK293 cell lineHEL299 cell lineHeLa cell lineOS143B cell lineTransportan 10 (TP10)

Identifiers

PMID26899863
PMCPMC4823340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.